At the 2021 virtual JP Morgan Healthcare Conference, Vertex Pharmaceuticals’ chief executive officer Reshma Kewalramani said the company is looking to buy “mid- and late-stage assets.”
RNAi-Focused Atalanta Therapeutics Launches
Alzheimer’s Disease, Biogen, Business, CNS Disorders, Collaborations, Company Launches, Deals, Financing, Genentech, Huntington’s disease, Neurodegenerative Diseases, Parkinson’s disease, RNA Interference (RNAi), RNAi therapeutics, Series A, Small Interfering RNA (siRNA)RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.
Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Roche company Genentech to identify and advance novel RNA-targeted small molecule therapeutics.
Skyhawk Therapeutics and Vertex Pharmaceuticals inked a strategic research collaboration and licensing deal focused on developing novel small molecules that modulate RNA splicing.
Immunai, a company comprehensively mapping the immune system, announced a collaboration with leading life science technology company 10x Genomics.
Relay Therapeutics entered a global license and collaboration agreement with Genentech for the commercialization and development of RLY-1971, a potent inhibitor of SHP2.
IPO Frenzy Continues as 4 More Go Public
Biopharma, Biosimulation, Biotech, Business, Cardiology, Clinical Trials, Collaborations, Consultancies, Coronavirus Disease 2019 (COVID-19), COVID-19 Antibodies, Drug Development, Drug Discovery, FDA, Initial Public Offering (IPO), Life Sciences, Ophthalmology, Pharma, R&D, Radioenhancersw, Roche, Shares, Solid TumorsFour more companies secured their place on the stock ticker in a record-breaking year before 2020 comes to a close.
Days after Bayer announced a new cell and gene therapy strategy to maximize the capabilities of some recent acquisitions, the Germany-based life sciences giant is jumping into the CAR-T space and expanding the company’s oncology focus through a collaboration with Bay Area-based Atara Biotherapeutics.
BioSpace Global Roundup: Ipsen Wins Fast Track Designation for Cancer Drug and More
3D, Antibody-Drug Conjugates (ADCs), Business, Clinical Trials, Collaborations, Coronavirus Disease 2019 (COVID-19), Data, E. Coli, Fast Track Designation, FDA, Gene Editing, Joint Ventures, Licensing, Metastatic pancreatic cancer, Neurological Disorders, R&D, Series A, Small cell lung cancer, Staphylococcus aureus infections, Therapeutics, Ulcerative Colitis, VaccinesParis-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.
Eli Lilly and Company and Precision BioSciences Inc. announced a research collaboration and exclusive license agreement to use Precision’s ARCUS genome editing platform to research and develop potential in vivo therapies for a series of genetic disorders.